6VIP
| TUDOR DOMAIN OF TUMOR SUPPRESSOR P53BP1 WITH MFP-6008 | Descriptor: | TP53-binding protein 1, UNKNOWN ATOM OR ION, {4-[(3,5-dimethyl-1H-pyrazol-1-yl)methyl]phenyl}(4-ethylpiperazin-1-yl)methanone | Authors: | The, J, Hong, Z, Dong, A, Headey, S, Gunzburg, M, Doak, B, James, L.I, Bountra, C, Arrowsmith, C.H, Edwards, A.M, Brown, P.J, Structural Genomics Consortium (SGC) | Deposit date: | 2020-01-13 | Release date: | 2020-02-12 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (1.36 Å) | Cite: | TUDOR DOMAIN OF TUMOR SUPPRESSOR P53BP1 WITH MFP-6008 to be published
|
|
6UPT
| Tudor Domain of Tumor suppressor p53BP1 with MFP-2706 | Descriptor: | 2-((2-chlorobenzyl)thio)-4,5-dihydro-1H-imidazole, TP53-binding protein 1, UNKNOWN ATOM OR ION | Authors: | The, J, Dong, A, Headey, S, Gunzburg, M, Doak, B, James, L.I, Bountra, C, Arrowsmith, C.H, Edwards, A.M, Brown, P.J, Structural Genomics Consortium (SGC) | Deposit date: | 2019-10-18 | Release date: | 2019-11-20 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (1.96 Å) | Cite: | Tudor Domain of Tumor suppressor p53BP1 with MFP-2706 to be published
|
|
6VA5
| Tudor Domain of Tumor suppressor p53BP1 with MFP-4184 | Descriptor: | 2-(4-methylpiperazin-1-yl)aniline, GLYCEROL, SULFATE ION, ... | Authors: | Zeng, H, Dong, A, Headey, S, Gunzburg, M, Doak, B, James, L.I, Bountra, C, Arrowsmith, C.H, Edwards, A.M, Brown, P.J, Structural Genomics Consortium (SGC) | Deposit date: | 2019-12-16 | Release date: | 2020-04-29 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (1.28 Å) | Cite: | Tudor Domain of Tumor suppressor p53BP1 with MFP-4184 to be published
|
|
8EOM
| TUDOR DOMAIN OF TUMOR SUPPRESSOR P53BP1 WITH MFP-5973 | Descriptor: | 4-(4-methylpiperazine-1-sulfonyl)benzamide, SULFATE ION, TP53-binding protein 1, ... | Authors: | The, J, Hong, Z, Headey, S, Gunzburg, M, Doak, B, James, L.I, Arrowsmith, C.H, Edwards, A.M, Brown, P.J, Structural Genomics Consortium (SGC) | Deposit date: | 2022-10-03 | Release date: | 2023-01-18 | Last modified: | 2023-10-25 | Method: | X-RAY DIFFRACTION (1.7 Å) | Cite: | TUDOR DOMAIN OF TUMOR SUPPRESSOR P53BP1 WITH MFP-5973 to be published
|
|
8F0W
| Tudor Domain of Tumor suppressor p53BP1 with MFP-5956 | Descriptor: | 1-[4-(4-ethylpiperazin-1-yl)-3-fluorophenyl]butan-1-one, TP53-binding protein 1, UNKNOWN ATOM OR ION | Authors: | The, J, Hong, Z, Dong, A, Headey, S, Gunzburg, M, Doak, B, James, L.I, Bountra, C, Arrowsmith, C.H, Edwards, A.M, Brown, P.J, Structural Genomics Consortium (SGC) | Deposit date: | 2022-11-04 | Release date: | 2023-01-18 | Last modified: | 2023-10-25 | Method: | X-RAY DIFFRACTION (1.52 Å) | Cite: | Tudor Domain of Tumor suppressor p53BP1 with MFP-5956 to be published
|
|
6BED
| Crystal structure of VACV D13 in complex with Rifampicin | Descriptor: | 1,2-ETHANEDIOL, FORMIC ACID, RIFAMPICIN, ... | Authors: | Garriga, D, Accurso, C, Coulibaly, F. | Deposit date: | 2017-10-25 | Release date: | 2018-07-18 | Last modified: | 2023-10-04 | Method: | X-RAY DIFFRACTION (2.75 Å) | Cite: | Structural basis for the inhibition of poxvirus assembly by the antibiotic rifampicin. Proc. Natl. Acad. Sci. U.S.A., 115, 2018
|
|
6BEC
| Crystal structure of VACV D13 in complex with Rifabutin | Descriptor: | 1,2-ETHANEDIOL, FORMIC ACID, RIFABUTIN, ... | Authors: | Garriga, D, Accurso, C, Coulibaly, F. | Deposit date: | 2017-10-25 | Release date: | 2018-07-18 | Last modified: | 2023-10-04 | Method: | X-RAY DIFFRACTION (2.91 Å) | Cite: | Structural basis for the inhibition of poxvirus assembly by the antibiotic rifampicin. Proc. Natl. Acad. Sci. U.S.A., 115, 2018
|
|
6BEG
| Crystal structure of VACV D13 F486A mutant | Descriptor: | 1,2-ETHANEDIOL, FORMIC ACID, Scaffold protein D13 | Authors: | Garriga, D, Accurso, C, Coulibaly, F. | Deposit date: | 2017-10-25 | Release date: | 2018-07-18 | Last modified: | 2023-10-04 | Method: | X-RAY DIFFRACTION (3.1 Å) | Cite: | Structural basis for the inhibition of poxvirus assembly by the antibiotic rifampicin. Proc. Natl. Acad. Sci. U.S.A., 115, 2018
|
|
6BEB
| Crystal structure of VACV D13 in complex with Rifamycin SV | Descriptor: | 1,2-ETHANEDIOL, FORMIC ACID, Scaffold protein D13, ... | Authors: | Garriga, D, Accurso, C, Coulibaly, F. | Deposit date: | 2017-10-25 | Release date: | 2018-07-18 | Last modified: | 2023-10-04 | Method: | X-RAY DIFFRACTION (2.55 Å) | Cite: | Structural basis for the inhibition of poxvirus assembly by the antibiotic rifampicin. Proc. Natl. Acad. Sci. U.S.A., 115, 2018
|
|
6BEH
| Crystal structure of VACV D13 in complex with Rifapentine | Descriptor: | 1,2-ETHANEDIOL, FORMIC ACID, RIFAPENTINE, ... | Authors: | Garriga, D, Accurso, C, Coulibaly, F. | Deposit date: | 2017-10-25 | Release date: | 2018-07-18 | Last modified: | 2023-10-04 | Method: | X-RAY DIFFRACTION (3 Å) | Cite: | Structural basis for the inhibition of poxvirus assembly by the antibiotic rifampicin. Proc. Natl. Acad. Sci. U.S.A., 115, 2018
|
|
6BEF
| Crystal structure of VACV D13 in complex with 3-formyl rifamycin SV | Descriptor: | (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-8-formyl-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptam ethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate, 1,2-ETHANEDIOL, FORMIC ACID, ... | Authors: | Garriga, D, Accurso, C, Coulibaly, F. | Deposit date: | 2017-10-25 | Release date: | 2018-07-18 | Last modified: | 2023-10-04 | Method: | X-RAY DIFFRACTION (3.21 Å) | Cite: | Structural basis for the inhibition of poxvirus assembly by the antibiotic rifampicin. Proc. Natl. Acad. Sci. U.S.A., 115, 2018
|
|
6BEE
| Crystal structure of VACV D13 in complex with Rifaximin | Descriptor: | (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-1,1 5-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)furo[2'',3'':7',8']naphtho[1',2':4,5]imidazo[1,2-a]pyridin-2 5-yl acetate, 1,2-ETHANEDIOL, FORMIC ACID, ... | Authors: | Garriga, D, Accurso, C, Coulibaly, F. | Deposit date: | 2017-10-25 | Release date: | 2018-07-18 | Last modified: | 2023-10-04 | Method: | X-RAY DIFFRACTION (3.11 Å) | Cite: | Structural basis for the inhibition of poxvirus assembly by the antibiotic rifampicin. Proc. Natl. Acad. Sci. U.S.A., 115, 2018
|
|
6BEI
| Crystal structure of VACV D13 in its apo (unbound) form | Descriptor: | 1,2-ETHANEDIOL, FORMIC ACID, Scaffold protein D13 | Authors: | Garriga, D, Accurso, C, Coulibaly, F. | Deposit date: | 2017-10-25 | Release date: | 2018-07-18 | Last modified: | 2023-10-04 | Method: | X-RAY DIFFRACTION (2.81 Å) | Cite: | Structural basis for the inhibition of poxvirus assembly by the antibiotic rifampicin. Proc. Natl. Acad. Sci. U.S.A., 115, 2018
|
|
8F47
| |
8F65
| |